Fundraising FoxvenBio Global Strategic — 2023 Investments
2 investments dated 2023 · listed companies and verified rows first · show all
Insamo develops an automated platform for drug discovery that designs, synthesizes, and tests cyclic peptides at scale using machine learning and proprietary experimental data.
AI & Machine LearningBiotechDeep TechChippendale, AU
Tim Craven(CEO)inToby Passioura(Founder)inGlen McIntyre(Founder)Timothy Craven(Founder)
BoardMATT HERSHENSON(Director)in
Board seatCorey Goodman· per SEC Form D · $2.3M raise · filed Dec 2023
Co-investorsBEVCCivilization Ventures Management, LlcMRL Ventures FundPlayground GlobalvenBio PartnersAxial VC
NFlection is a biopharmaceutical company developing novel therapeutics.
BiotechMedical DevicesBoston, US
Christopher Powala(Chief Development Officer, Former President & CEO)Mark de Souza(Executive Officer, Director)in
BoardKetan Patel(Director)in
Board seatCorey Goodman· per SEC Form D · $4M raise · filed Jul 2023
Co-investorsF-Prime CapitalvenBio Partners
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.